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Abstract
Purpose Optic pathway gliomas, which occur in 15–20%
of paediatric patients with neurofibromatosis type 1, are the
most common central nervous system tumour associated
with this neurocutaneous disorder. The detection of optic
pathway gliomas is essential for further management but is
often delayed in infancy due to oligosymptomatic progres-
sion and difficulties in clinical detection. Therefore, the aim
of our study was to find a clinical indicator for the presence
of optic pathway gliomas in children with neurofibromato-
sis type 1 in order to facilitate early diagnosis and initiate
further ophthalmological and neuroimaging investigations.
Methods We retrospectively evaluated 70 patients (mean
age of 10.5 years; SD of 4.3 years; range of 0.5–19.6 years;
35 females) with neurofibromatosis type 1 seen at the
University Children’s Hospital of Bern, Switzerland, be-
tween January 1998 and December 2008 regarding clinical
features of neurofibromatosis type 1 in relation to the
presence of optic pathway gliomas.
Results Fifty-seven of the 70 patients (81.4%) had no
clinical or radiological signs of optic pathway gliomas
[magnetic resonance imaging (MRI) of the brain in 26/57],
whereas 13/70 patients (18.6%) were diagnosed with optic
pathway gliomas by MRI. Patients with optic pathway
gliomas showed macrocephaly significantly more often
compared to patients without optic pathway gliomas (8/13
vs. 9/57, respectively; p=0.004).
Conclusion Macrocephaly significantly correlates with the
incidence of optic pathway gliomas in children with
neurofibromatosis type 1. We therefore hypothesise that in
otherwise asymptomatic patients, macrocephaly is an
additional indicator for performing MRI to detect optic
pathway gliomas.
Keywords Neurofibromatosis-type 1 . Optic pathway
gliomas .Macrocephaly . Children .MRI
Introduction
Neurofibromatosis type 1 (NF1) is an autosomal dominant
neurocutaneous genetic disorder occurring with an estimat-
ed incidence of 1:3,000 individuals per year, independent of
ethnicity, race and gender [1]. The hallmarks of the clinical
condition are the development of pigmentary lesions (café-
au-lait spots, skinfold freckling and Lisch nodules),
distinctive skeletal lesions (sphenoid dysplasia and pseu-
doarthrosis) and tumours, such as optic pathway gliomas
and neurofibromas [2].
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The NF1 gene product, neurofibromin, is known to act
as a tumour suppressor [3]. Loss of neurofibromin leads to
increased activity of the Ras signalling pathway and
therefore to accelerated cell growth with astrocyte prolifer-
ation [3, 4]. However, in the developing brain, the NF1
gene also functions as a cell growth regulator and seems to
play a role in neuronal differentiation [5]. Disturbed cell
growth regulation might be the backbone of an abnormal
brain development, as seen in the 20% rate of learning
disabilities in paediatric NF1 patients [6].
Optic pathway gliomas (OPGs) are the predominant
cerebral tumour in NF1, affecting 15–20% of all children
with NF1 within their first decade of life [7]. Histologically,
OPGs are almost uniformly pilocytic astrocytomas (WHO
grade I). Many of these tumours show prolonged indolent
phases, whereas others progress rapidly. In addition, OPGs
can have erratic growth patterns or may demonstrate
spontaneous regression [8, 9]. However, only 30–50% of
children with NF1 and OPGs develop clinical symptoms
such as decreased visual acuity, proptosis or precocious
puberty, thus making an early diagnosis difficult [10].
In an attempt to facilitate early diagnosis of OPGs in
asymptomatic and oligosymptomatic children with NF1,
the present study analysed clinical characteristics such as
macrocephaly, epilepsy, headache/migraine, scoliosis, neu-
rocognitive deficits and behavioural abnormalities in order
to determine additional indicators for early ophthalmologic
and neuroimaging investigations.
Materials and methods
This study complied with Health Insurance Portability and
Accountability Act and was approved by our institutional
review board. In addition, the requirement for an informed
consent was waived. The current study is a retrospective
review of all consecutive paediatric and adolescent patients
with NF1 referred to the University Children’s Hospital in
Bern, Switzerland, between 1 January 1998 and 31 December
2008. On a routine basis, these children were seen over a
yearly schedule by a neuropaediatrician and an ophthalmolo-
gist. Study enrolment required that the subjects fulfilled the
diagnostic criteria of the 1988 National Institutes of Health
(NIH) Consensus Development Conference for Neurofibro-
matosis Type 1 [2]. Patient charts and radiology records were
reviewed for data relating to patient demographics, the
clinical distribution of NIH criteria (café-au-lait spots,
skinfold freckling, Lisch nodules, skeletal dysplasia, neuro-
fibromas, optic pathway gliomas and a first-degree relative
who was positive for NF1) and the presence of NF1-related
neurological abnormalities (macrocephaly, epilepsy, head-
ache/migraine, scoliosis and neurocognitive deficits such as
learning deficits and behavioural abnormalities).
Patients were further divided into two groups: children with
NF1 without OPGs (group 1) and children with NF1 and the
presence of OPGs (group 2). OPGs were solely diagnosed by
magnetic resonance imaging (MRI) of the brain. Imaging
techniques were performed by clinical indication in children
Group 1 patients (NF1 without
OPGs) n=57/70 (81.4%)
Group 2 patients: (NF1 with
OPGs) n=13/70 (18.6%)
p value
Mean age, in years, at
last consultation [SD]
(Student’s t test)
10.6 [4.6] 10.1 [3.4] 0.733
Café-au-lait spots 56/57 (98.3%) 13/13 (100%) 1.000
Skinfold freckling 39/57 (68.4%) 12/13 (92.3%) 0.167
Lisch nodules 3/57 (5.3%) 2/13 (15.4%) 0.255
Skeletal dysplasia 7/57 (12.3%) 2/13 (15.4%) 1.000
Neurofibromas 20/57 (35.1%) 4/13 (38.5%) 1.000
Positive family history 24/57 (42.1%) 5/13 (38.5%) 1.000
Table 1 Results of the Barnard’s
test: comparison of group 1
(NF1 without OPGs) and group
2 (NF1 with OPGs) patients
regarding NIH criteria
OPGs optic pathway gliomas,
NF1 neurofibromatosis type 1
Group 1 patients (NF1
without OPGs) n=57 (81.4%)
Group 2 patients (NF1
with OPGs) n=13 (18.6%)
p value
Macrocephaly 9/57 (15.8%) 8/13 (61.5%) 0.004a
Epilepsy 2/57 (3.5%) 2/13 (15.4%) 0.183
Headache/migraine 10/57 (17.5%) 0/13 (0%) 0.183
Scoliosis 22/57 (38.6%) 5/13 (38.5%) 1.000
Learning disabilities 19/57 (33.3%) 6/13 (46.2%) 0.472
Behavioural abnormalities 17/57 (29.8%) 2/13 (15.4%) 0.367
Unknown bright objects (UBOs) 15/26 (57.7%) 11/13 (84.6%) 0.120
Table 2 Results of the Barnard’s
test: comparison of group 1 (NF1
without OPGs) and group 2 (NF1
with OPGs) patients regarding
NF1-associated features and the
presence of unknown bright
objects
OPGs optic pathway gliomas,
NF1 neurofibromatosis type 1
a Statistically significant
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with symptoms or medical findings in a routine examination
that required further investigation (e.g. headache, neurological
abnormalities or decreased visual acuity). All images were
reviewed at the time of imaging by an experienced neuroradi-
ologist for the presence of OPGs or other brain tumours. At the
time of study accomplishment, the images were re-evaluated
regarding a ventricle/parenchyma ratio by measuring the cross
diameter of the third ventricle at the level of the thalami and the
cross diameter of the parenchyma at the level of the foramina of
Monro to differentiate hydrocephalus from megalencephaly.
Furthermore, tumours were classified radiologically according
to the number and location. Diagnosed patients with OPG
were further evaluated regarding symptoms related to OPG
and the initiated therapy.
Using the Student’s t test for the ventricle/parenchyma
ratio and the Barnard’s test for the remaining calculations, we
calculated possible differences among the variables between
the two patient groups [11]. The null hypothesis was that
both groups are equal. The hypothesis was rejected if p<0.05
in a two-tailed analysis (Tables 1, 2 and 3).
Results
During the 10-year study period, 70 children [mean age at
last follow-up of 10.5 years; standard deviation (SD) of
4.3 years; range of 0.5–19.6 years; 35 females] with NF1
were referred to the University Children’s Hospital in Bern.
MRI was performed in 55.7% (39/70) of the participating
patients, broken down as 45.6% (26/57) of group 1 patients
and all patients of group 2 (13/13). Fifty-seven of the 70
(81.4%) patients had no clinical or radiological evidence of
OPGs (group 1, mean age at last presentation of 10.6 years;
SD of 4.6 years; 29 females), whereas 13/70 (18.6%)
patients were diagnosed with OPG by MRI of the brain
(group 2, mean age at last presentation of 10.1 years; SD of
3.4 years; six females) (Table 1). There was no significant
difference between the groups regarding the distribution of
NIH criteria, except for the presence of OPGs (Table 1).
However, 15.8% of group 1 patients showed macro-
cephaly compared to 61.5% of group 2 patients. This
difference was statistically significant (p=0.004) (Table 2).
In group 1 patients with macrocephaly, two of nine (7.7%)
had an MRI of the brain, whereas 24/48 (54.2%) group 1
patients without macrocephaly had an MRI of the brain (p=
0.189) (Table 3). Limiting the number to children who have
had MRI of the brain shows that 2/26 (7.7%) group 1
patients had macrocephaly, whereas 8/13 (61.5%) group 2
patients had macrocephaly. This difference was still
statistically significant (p=0.0001) (Table 4). Evaluating
the ventricle/parenchyma ratio at the level of the third
ventricle of group 1 (measured in 21/26) and group 2
(measured in 11/13) patients showed no statistical signifi-
cance (0.22 vs. 0.26; p=0.620). In two of two (100%)
group 1 patients with macrocephaly, unknown bright
objects (UBOs) were identified on the MRI of the brain,
while only 13/24 (54.2%) group 1 patients without macro-
cephaly had UBOs on the MRI of the brain (p=0.365)
(Table 3). Group 2 patients with and without macrocephaly
did not show any differences regarding the presence of
UBOs (87.5% vs. 80.0%; p=0.849) (Table 3). In addition,
there were no statistically significant differences regarding
Table 3 Results of the Barnard’s test: comparison of group 1 (NF1 without OPGs) and group 2 (NF1 with OPGs) patients with and without
macrocephaly regarding the performance of an MRI of the brain and the presence of unknown bright objects
Group 1 patients
(NF1 without OPGs)











MRI of the brain 2/9 (7.7%) 24/48 (54.2%) 0.189 8/8 (61.5%) 5/5 (38.5%) 1.000
Unknown bright objects
(UBOs)
2/2 (100%) 13/24 (54.2%) 0.365 7/8 (87.5%) 4/5 (80.0%) 0.849
OPGs optic pathway gliomas, NF1 neurofibromatosis type 1, MRI magnetic resonance imaging
Table 4 Results of the Barnard’s test: comparison of group 1 (NF1 without OPGs) and group 2 (NF1 with OPGs) patients with both
macrocephaly and MRI of the brain
Group 1 patients (NF1 without OPGs)
with MRI of the brain n=26
Group 2 patients (NF1 with OPGs)
with MRI of the brain n=13
p value
Macrocephaly 2/26 (7.7%) 8/13 (61.5%) 0.0001a
OPGs optic pathway gliomas, NF1 neurofibromatosis type 1, MRI magnetic resonance imaging
a Statistically significant
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epilepsy, headache/migraine, scoliosis, learning disabilities
and behavioural abnormalities (Table 2).
Regarding the presence of OPGs, 10/13 (76.9%) group 2
patients had chiasmal OPGs, whereas 4/13 (30.7%) had
OPGs involving one optic nerve or both optic nerves,
separately, and 2/13 (15.4%) group 2 patients showed
OPGs affecting the optic tract. Six of 13 (46.2%) patients
initially presented with visual impairment, and 2/13
(15.4%) showed elevated intracranial pressure due to
additional cerebral gliomas. However, 5/13 (38.5%)
patients of group 2 were asymptomatic.
Chemotherapeutic treatment with drugs (carboplatin,
etoposide and temozolamide) was started in 3/13 (23.1%)
patients due to progressive visual impairment. These
patients were between 9 and 10 years of age at the last
follow-up, and all had significant visual impairment (visual
acuity <0.3). The remaining patients showed no, or mild,
visual impairment.
Discussion
The aim of our study was to find besides visual problems a
clinical indicator for the presence of OPGs in paediatric
patients with NF1 in order to facilitate early diagnosis and
to initiate MRI of the brain as early as necessary. Our
results show that macrocephaly correlates significantly with
the presence of OPGs in paediatric patients with NF1,
whom are also otherwise asymptomatic patients. Macro-
cephaly, defined as a head circumference two or more
standard deviations above the sex- and age-matched
population’s mean, has clearly been associated with NF1,
occurring in 25–50% of all patients with NF1 [12–14].
Macrocephaly was revealed in 24% of patients in our
cohort. However, 61.5% of NF1 patients with OPGs
demonstrated macrocephaly, whereas only 15.8% of NF1
patients without OPGs had macrocephaly. Neuroimaging of
all the patients might have increased the number of patients
with OPG. However, our results were still significant
limiting the number to children who have had MRI of the
brain. The likelihood of developing OPG after normal MRI
of the brain and careful clinical and ophthalmological
follow-up must be considered minimal.
In NF1, macrocephaly is caused by megalencephaly,
which is defined as the enlargement of brain tissue [12].
This enlargement is mainly due to a significant increase in
white matter volume when compared to normocephalic
NF1 patients [12]. In addition to brain enlargement, 60–
70% of NF1 patients show so-called UBOs in the brain
tissue that are characteristic focal lesions of increased signal
intensity on T2-weighted MRIs [14, 15]. These lesions
reflect dysplastic glial proliferations in the developing brain
[15, 16] and are significantly related to lower IQs in NF1-
affected children [15, 17]. Thus far, only Steen et al. could
demonstrate a correlation between the presence of bilateral
UBOs and macrocephaly in paediatric patients with NF1
[12]. In the present study, UBOs were more frequently seen
in patients with than without OPGs, but this difference was
not statistically significant because of the small patient
number. In summary, these NF1-specific alterations suggest
that children with macrocephaly, UBOs and OPGs might
have lower levels of neurofibromin and therefore more
pronounced accelerated cell growth. Moreover, Szudek et
al. studied statistical associations among 13 of the most
important and common clinical features in NF1 [18]. It was
reported that macrocephaly and OPGs have strong associ-
ations, suggesting that glial hyperplasia is responsible not
only for macrocephaly but also for the development of
optic pathway gliomas [13, 18, 19].
Currently, routine neuroimaging screening for OPGs in
asymptomatic paediatric patients is not recommended [20].
However, children younger than 6 years of age are at the
greatest risk of OPG development [7]. In this age group, the
expression of decreased visual acuity, as the most common
clinical symptom in patients with OPGs, is unreliable [20].
Limitations of our study must be acknowledged. Data
were collected retrospectively, and imaging techniques were
not performed in all 70 patients. Therefore, it might be
possible that some undiagnosed patients with OPGs were
false subjects of group 1. Furthermore, the number of
participants in the present study was quite small, so larger
studies are necessary to confirm our findings. We conclude
that macrocephaly may be useful as a quick and inexpen-
sive indicator for performing an MRI of the brain or
thorough ophthalmological investigations in otherwise
asymptomatic paediatric patients with NF1 to scan for
OPGs.
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